Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

657 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS).
Evans SR, Follmann D, Liu Y, Holland T, Doernberg SB, Rouphael N, Hamasaki T, Jiang Y, Lok JJ, Tran TTT, Harris AD, Fowler VG, Boucher H, Kreiswirth BN, Bonomo RA, Van Duin D, Paterson DL, Chambers H. Evans SR, et al. Among authors: hamasaki t. Clin Infect Dis. 2019 May 17;68(11):1961-1967. doi: 10.1093/cid/ciy912. Clin Infect Dis. 2019. PMID: 30351426 Free PMC article.
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials.
Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Hill C, Gelone SP, Mariano D, Baba T, Holland TL, Doernberg SB, Chambers HF, Fowler VG, Evans SR, Boucher HW. Howard-Anderson J, et al. Among authors: hamasaki t. Clin Infect Dis. 2023 Feb 8;76(3):e1157-e1165. doi: 10.1093/cid/ciac692. Clin Infect Dis. 2023. PMID: 36031403 Free PMC article.
Group-sequential three-arm noninferiority clinical trial designs.
Ochiai T, Hamasaki T, Evans SR, Asakura K, Ohno Y. Ochiai T, et al. Among authors: hamasaki t. J Biopharm Stat. 2017;27(1):1-24. doi: 10.1080/10543406.2016.1148710. Epub 2016 Feb 18. J Biopharm Stat. 2017. PMID: 26892481 Free PMC article.
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA, Zaharoff S, King H, Evans S, Hamasaki T, Lodise T, Ghazaryan V, Beresnev T, Riccobene T, Patel R, Doernberg SB, Rappo U, Fowler VG Jr, Holland TL; Antibacterial Resistance Leadership Group (ARLG). Turner NA, et al. Among authors: hamasaki t. Trials. 2022 May 16;23(1):407. doi: 10.1186/s13063-022-06370-1. Trials. 2022. PMID: 35578360 Free PMC article.
A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection.
Howard-Anderson J, Dai W, Yahav D, Hamasaki T, Turjeman A, Koppel F, Franceschini E, Hill C, Sund Z, Chambers HF, Fowler VG Jr, Boucher HW, Evans SR, Paul M, Holland TL, Doernberg SB. Howard-Anderson J, et al. Among authors: hamasaki t. Open Forum Infect Dis. 2022 Apr 9;9(6):ofac140. doi: 10.1093/ofid/ofac140. eCollection 2022 Jun. Open Forum Infect Dis. 2022. PMID: 35615299 Free PMC article.
Analysis of ordered composite endpoints.
Follmann D, Fay MP, Hamasaki T, Evans S. Follmann D, et al. Among authors: hamasaki t. Stat Med. 2020 Feb 28;39(5):602-616. doi: 10.1002/sim.8431. Epub 2019 Dec 19. Stat Med. 2020. PMID: 31858640 Free PMC article.
657 results